• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Genentech

Genentech

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. FDA Grants Genentech ’s Cancer Immunotherapy TECENTRIQ® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer

    FDA Grants Genentech ’s Cancer Immunotherapy TECENTRIQ® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer

  2. Genentech ’s Emicizumab for Hemophilia A Meets Primary Endpoint in Phase III Study

    Genentech ’s Emicizumab for Hemophilia A Meets Primary Endpoint in Phase III Study

  3. Positive Phase III Results of Genentech ’s Investigational Medicine OCREVUS™ (Ocrelizumab) Published in New England Journal of Medicine

    Positive Phase III Results of Genentech ’s Investigational Medicine OCREVUS™ (Ocrelizumab) Published in New England Journal of Medicine

  4. Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  5. ImmunoGen Announces Webcast of Presentation and Q&A at the 35th Annual J. P. Morgan Healthcare Conference

    ImmunoGen Announces Webcast of Presentation and Q&A at the 35th Annual J. P. Morgan Healthcare Conference

  6. Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of cabozantinib to include Canada

    Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of cabozantinib to include Canada

  7. Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada

    Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada

  8. Chugai's Bispecific Antibody "Emicizumab" for Hemophilia A Meets Primary Endpoint in Phase lll Study

    Chugai's Bispecific Antibody "Emicizumab" for Hemophilia A Meets Primary Endpoint in Phase lll Study

  9. Social Security Tips For Couples

    Genentech DNA reported strong first-quarter revenue and earnings growth compared with the year-ago period, and we are sticking with our fair value estimate. As the company warned at its investor meeting in March, quarter-over-quarter product sales growth was stagnant, while total revenue growth ...

  10. Tuttle Tactical Management Weekly Market Commentary

    Genentech DNA continues to focus attention on its commercial lineup, making its slimmer early-stage pipeline not worrisome yet. The biotech firm has additional clinical trials and hopes to expand indications for each of its largest products, including Avastin, Herceptin, and Rituxan. According to ...

123
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.